Triana Launches With $110m Funding For Developing Molecular Glues

Joins Buzzing TPD Space

The Massachusetts-based biotech’s fundraise will be used to discover and develop molecular glues with an initial focus on cancer targets.  

Triana Plans To Develop Molecular Glues For Cancer • Source: Alamy

The trending targeted protein degradation R&D space has seen a new entry with the 6 April launch of Triana Biomedicines, Inc., a US firm focused on novel molecular glues, which has raised $110m in a series A.

The Waltham, MA-headquartered firm said the money would be used to establish a potentially best-in-class, scalable platform to facilitate the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Financing

More from Business

Novartis Upbeat Even With Entresto Expiry Looming

 
• By 

Swiss major confident that new oncology drugs will fill revenue gap.

China Sentences Astellas Employee To 3.5 Years In Prison On Spy Charges

 
• By 

An employee of Astellas faces three and a half years in prison after sentencing by a court in China on espionage charges.

Sarepta Restructures, Cuts 500 Jobs As Elevidys-Related Deaths Impact Sales

 
• By 

After a second quarter of declining Elevidys sales following two deaths of DMD patients treated with the gene therapy, Sarepta is cutting costs to fund remaining programs and meet debt requirements.